"This represents, to our knowledge, the first demonstration of the ability of any blood-sugar-lowering agent to slow the progression of coronary atherosclerosis in patients with diabetes," says researcher Steven E. Nissen, MD, chairman of cardiovascular medicine at Cleveland Clinic.
"This will change the paradigm of how we treat people with diabetes," he tells WebMD. "It's not how much you lower blood sugar, but how you lower it."
The study was presented at the annual meeting of the American College of Cardiology and simultaneously released online by The Journal of the American Medical Association.
How Actos and Amaryl Work
Nissen and colleagues studied more than 350 people with type 2 diabetes and cardiovascular disease. About half were given Actos, a member of a relatively new class of antidiabetic agents known as thiazolidinediones.
The rest were given Amaryl. It's a member of the class of agents known as sulfonylureas that have been available for decades and represent one of the most commonly prescribed classes of diabetic therapy.
Actos and Amaryl work very differently. Actos makes the body more sensitive to insulin. Amaryl stimulates the pancreas to release more insulin.
Actos carries a "black box" warning that the drug may trigger heart failure, but it has not been linked to any increased risk of heart attack.
Actos Slows Plaque Buildup
All the participants underwent ultrasounds at the start of the study and about 18 months later to determine changes in the plaque buildup within the coronary arteries.
Results showed that Actos halted the dangerous progression of atherosclerosis and even started to reverse it, Nissen says. In contrast, plaque continued to build up in the arteries of patients who took Amaryl.